ClinicalTrials.gg
CompletedNCT06385509Updated Oct 2, 2026

A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months

A Phase 4 interventional study of Jatenzo Oral Product in Hypogonadism, sponsored by Tolmar Inc.. Completed at 27 sites in United States. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Tolmar Inc. · Phase 4, Interventional, and Treatment

How we know

Updated Oct 2, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
116
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing testosterone undecanoate in Hypogonadism — 3 open to participants now, 3 under way, none of them phase 3. testosterone undecanoate · Hypogonadism.

Enrollment
9th of 26
116 · median 56
Started
2024
with 1 other
Phase 4
7 of 26
none open now
Registered
25th of 26
by date

Among the 26 studies testing testosterone undecanoate in Hypogonadism, this one is the 9th largest by enrollment, is one of 2 that started in 2024, is one of 7 in phase 4, and was the 25th registered.

Hypogonadism

320 studies on the registry are indexed under Hypogonadism; 39 are open to participants now.

Browse Hypogonadism studies →

Open to participants now

3 of the 26 studies testing testosterone undecanoate in Hypogonadism are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About testosterone undecanoate

testosterone undecanoate: first FDA approval 2014 (AVEED), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 Hypogonadism studies recruiting now, 9 (38%) set no upper age limit and 12 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing testosterone undecanoate in Hypogonadism, or all of them as a file.
02

Study summary

TOL-CLAR-20024 is a Phase 4, multi-center, open-label safety study evaluating the potential effect of JATENZO on adrenal function in hypogonadal men treated with JATENZO for 12 months.

Read the detailed description

Following all screening activities and confirmation that the subject has met all eligibility requirements, JATENZO treatment for approximately 1 year will begin. The dose of JATENZO will be titrated using its standard dose-titration algorithms based on serum testosterone levels. The Treatment Period will consist of Visits 1 - 12, with cosyntropin stimulation test completed at Visit 9 (Day 169 ±7) and Visit 12 (Day 365 ±7). At each visit during the Treatment Period, subjects will be evaluated for signs and symptoms of adrenal insufficiency, occurrence of adverse events, and changes in concomitant medications. There will be a safety follow-up visit 2 weeks after completion of Visit 12.

03

Conditions studied

  • Hypogonadism

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be a man 18 to 65 years of age, inclusive, with a previous clinical diagnosis of hypogonadism (signs/symptoms consistent with hypogonadism and a low T level as defined by established criteria at the time of diagnosis); subjects must also have at least 1 T level \< 300 ng/dL at either Screen 1 or Screen 2.
  2. Subject must be naïve to androgen replacement therapy or washed out of prior androgen replacement therapies (wash out durations specified in exclusion criterion); that is, be willing to cease current T treatment, or currently not be taking T treatment.
  3. Subject agrees as part of signed to remain off all forms of T, except for dispensed study drug, throughout the entire study.
  4. Subject must have adequate venous access in the left or right arm to allow collection of blood samples.
  5. Subject must be able and willing to provide written informed consent and comply with the trial protocol and procedures.

Exclusion criteria

Exclusion Criteria:

  • Subject will be excluded if 1 or more of the main exclusion is applicable:

    1. Subject with a history of panhypopituitarism or multiple endocrine deficiencies (whether or not on stable doses of thyroid hormone and adrenal replacement hormones).
    2. Subject with a current or prior history of AI.
    3. Subject is currently receiving .
    4. On the CST at Screen 3, the maximum serum total cortisol at both the 30- and 60-minute timepoint is ≤ 14 mcg/dL or has a baseline CBG outside the reference range.
    5. Subject with a history of a short course (2 weeks or less) of any glucocorticoids within the past 3 months or anabolic steroids other than testosterone within the past 6 months.
    6. Subject with a history of a protracted course of any glucocorticoid therapy (e.g., inhaled nasal steroids, inhaled oral steroids, topical steroids, injectable steroids such as joint injections) or anabolic steroids other than T. Enrolled subjects who take glucocorticoids while on study drug may be discontinued from the study at the discretion of the investigator in consultation with the sponsor.
    7. Subject with a history of anabolic steroid abuse.
    8. Subject with a diagnosis of hypogonadism who has received any topical (e.g., gel or patch), intranasal, or buccal T therapy within the previous 2 weeks, intramuscular T injection of short-acting duration (e.g., T enanthate, T cypionate) within the previous 4 weeks, intramuscular T injection of long-acting duration (e.g., AVEED®) within the previous 20 weeks, T implantable pellets (Testopel®) product within the previous 6 months or any prior use of an oral testosterone product.
    9. Subject has received any drug as part of another research study within 30 days of initial dose administration in this study.
    10. Subject has significant intercurrent disease (e.g., liver, kidney, inflammatory bowel disease, uncontrolled or poorly controlled heart disease, including hypertension, thromboembolism, congestive heart failure, or coronary heart disease, psychiatric illness, including severe depression), which in the opinion of the Investigator, would affect study participation or interpretation of study assessments.
    11. Subject has untreated, severe obstructive sleep apnea.
    12. Subject has abnormal laboratory values, including serum transaminases > 2 × (ULN), serum > 1.5 × ULN (except subjects with Gilbert syndrome) and serum creatinine > 1.5 × ULN.
    13. Subject has a HCT value of \< 35% or > 50%.
    14. Subject has a history of polycythemia, either idiopathic or associated with TRT treatment.
    15. Subject is diabetic with a glycosylated > 8.5%.
    16. Subject has a (BMI) ≥ 38 kg/m2.
    17. Subject has had a recent (within 2 years) history of stroke, , or acute coronary event.
    18. Subject has a mean (triplicate assessments) systolic blood pressure (sBP) > 140 mm Hg and/or diastolic blood pressure (dBP) > 90 mm Hg at screening (if prescribed antihypertensives, subject should be taking medications on the day of the screening visit with a sip of water).
    19. Subject has had recent (within 2 years) history of angina or stent (coronary or carotid) placement.
    20. Subject does not meet the requirements for concomitant medication as outlined below:

      1. If hypertensive, on a stable dose of antihypertensive medication for \< 3 months
      2. If diabetic, on a stable dose of oral medication for \< 2 months
      3. If on anticonvulsant therapy, on a stable dose for \< 3 months
      4. If on lipid lowering medications, on a stable dose for \< 3 months. Subject is expected to remain on a stable dose of lipid-lowering medication(s) throughout the study.
    21. Subject has an abnormal prostate DRE (palpable nodules), elevated PSA (serum PSA > 4.0 ng/mL), I-PSS > 19 points at screening.
    22. Subject has a history of, or current or suspected prostate cancer.
    23. Subject has a history of, or current or suspected breast cancer.
    24. Subject currently using a drug known to affect T levels, T metabolism or levels of T metabolites. These include: 5-alpha-reductase inhibitors (e.g., dutasteride, finasteride), estrogens, long-acting opioid analgesics (e.g., methadone hydrochloride, buprenorphine hydrochloride), human growth hormone (HGH) or over-the-counter supplements purported to "boost" testosterone, sexual function or improve prostate symptoms.
    25. Subject use of dietary supplements such as saw palmetto or phytoestrogens and any dietary supplements that may increase total T, such as androstenedione or dehydroepiandrosterone within the previous 4 weeks.
    26. Subject use of any over-the-counter "adrenal supplements".
    27. Subject is not willing to stop all supplemental biotin 3 days prior to testing at intervals described in this protocol.
    28. Subject currently using Megace, atypical anti-psychotics (e.g., clozapine, aripiorazole, asenapine, lumateperone, olanzapine, paliperidone, aripiprazole, ziprasidone, cariprazine, risperidone, pimavanserin, ioperidone, brexpiprazole, lurasidone, quetiapine) or chronic benzodiazepine use.
    29. Subject has a history of abnormal bleeding tendencies or thrombophlebitis unrelated to venipuncture or intravenous cannulation within the previous 2 years.
    30. Subject has history of abuse of alcohol or any drug substance within the previous 2 years.
    31. Subject deemed to be a compliance risk or unlikely to keep clinic appointments.
    32. Subject donated blood (≥ 500 mL) within the 12-week period before the initial study dose.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    JATENZO® twice daily

    JATENZO capsules will be provided in 3 dosage strengths: 158 mg, 198 mg, 237 mg twice daily

    Drug: Jatenzo Oral Product

Interventions

06

What researchers measure

Primary outcomes

  1. CST Test

    To estimate the proportion of subjects with an abnormal post-stimulation cosyntropin stimulation test (CST) serum total cortisol level after approximately 6 and 12 months of treatment with JATENZO

    Time frame: 6 months and 12 months

Secondary outcomes

  1. Adrenal Insufficiency

    To estimate the proportion of subjects who develop primary adrenal insufficiency (AI) as assessed by clinical symptoms of AI and laboratory assessment of cortisol production after approximately 12 months of treatment with JATENZO

    Time frame: 12 months

Other outcomes

  1. Hormone changes

    To estimate the changes from baseline in estrogen (E), follicle stimulating hormone (FSH), and luteinizing hormon (LH) after approximately 3 and 6 months of treatment with JATENZO

    Time frame: 3 months and 6 months

  2. Sperm analysis

    To estimate the changes from baseline in sperm concentration, sperm motility, and total motile sperm count (TMSC) after approximately 3 and 6 months of treatment with JATENZO

    Time frame: 3 months and 6 months

  3. Testis volume analysis

    To estimate the changes from baseline in testicular size after approximately 3 and 6 months of treatment with JATENZO

    Time frame: 3 months and 6 months

07

Study locations

27 sites
  • Alliance for Multispecialty Research
    Tempe, Arizona 85281, United States
  • Clinical Trials Research
    Lincoln, California 95648, United States
  • Long Beach Research Institute, LLC
    Long Beach, California 90805, United States
  • Integrated Clinical Research
    Tarzana, California 91356, United States
  • Hillcrest Medical Research, LLC
    DeLand, Florida 32720, United States
  • Global Health Clinical Trial Crop
    Miami, Florida 33135, United States
  • Reserka LLC
    Miami, Florida 33176, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Clinical Research Center of Florida
    Pompano Beach, Florida 33060, United States
  • Velocity Clinical Research
    Savannah, Georgia 31406, United States
  • Centennial Medical Group
    Columbia, Maryland 21045, United States
  • Velocity Clinical Research
    Omaha, Nebraska 68134, United States
  • AccuMed Research Associates
    Garden City, New York 11530, United States
  • Rochester Clinical Research, LLC
    Rochester, New York 14609, United States
  • Velocity Clinical Research, Inc.
    Durham, North Carolina 27701, United States
  • Catawba Valley Medical Group, Inc.
    Hickory, North Carolina 28602, United States
  • Raleigh Medical Group
    Raleigh, North Carolina 27609, United States
  • Piedmont Healthcare, PA
    Statesville, North Carolina 28625, United States
  • Wilmington Health, PLLC
    Wilmington, North Carolina 28401, United States
  • Velocity Clinical Research
    Austin, Texas 78759, United States
  • Epic Medical Research LLC
    DeSoto, Texas 75115, United States
  • VAST Clinical Research LLC
    Garland, Texas 75041, United States
  • SMS Clinical Research LLC
    Mesquite, Texas 75149, United States
  • Alpine Research Organization, Inc.
    Clinton, Utah 84015, United States
  • Highland Clinical Research
    Salt Lake City, Utah 84124, United States
  • Alliance for Multispecialty Research
    Norfolk, Virginia 23507, United States
  • Clinical Investigation Specialists, Inc.
    Kenosha, Wisconsin 53144, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Nov 2025, 16 months.

Of 21 phase 4 interventional studies under Hypogonadism, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 72. This study's 16 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: start May 2024 → Jul 2024 and completion Mar 2026 → Nov 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2024
First posted
Apr 26, 2024
StartActual
Jul 2, 2024was May 2024
Primary completionActual
Nov 25, 2025
CompletionActual
Nov 25, 2025was Mar 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 2, 2026
Start date
May 10, 2024→Jul 2, 2024
Oct 2, 2026
Study completion
Mar 2026→Nov 25, 2025 (actual)
Oct 2, 2026
Enrollment
110→116
Oct 2, 2026
Interventions
Changed Jatenzo→Jatenzo Oral Product
Oct 2, 2026
Secondary outcomes
1 edited, 4 removed, 1 description edited
What changed in the outcomes
  • Editedother outcomeEstrogenHormone changesTime frame: 3 months and 6 months
  • Removedother outcomeFollicle Stimulating Hormone (FSH) changes.Time frame: 3 months and 6 months
  • Removedother outcomeLuteinizing hormone (LH) changesTime frame: 3 months and 6 months
  • Removedother outcomeSperm analysisTime frame: 3 months and 6 months
  • Removedother outcomeSperm analysisTime frame: 3 months and 6 months
  • Descriptionother outcomeSperm analysis: how it is measured was reworded
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Active, not recruiting→Completed
    Start date May 10, 2024→Jul 2, 2024
    Study completion Mar 2026→Nov 25, 2025 (now actual)
    Enrollment 110→116
    Secondary outcomes 1 edited, 4 removed, 1 description edited
    What changed in the outcomes
    • Editedother outcomeEstrogenHormone changesTime frame: 3 months and 6 months
    • Removedother outcomeFollicle Stimulating Hormone (FSH) changes.Time frame: 3 months and 6 months
    • Removedother outcomeLuteinizing hormone (LH) changesTime frame: 3 months and 6 months
    • Removedother outcomeSperm analysisTime frame: 3 months and 6 months
    • Removedother outcomeSperm analysisTime frame: 3 months and 6 months
    • Descriptionother outcomeSperm analysis: how it is measured was reworded
    Interventions Changed Jatenzo→Jatenzo Oral Product
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06385509
Lead sponsor
Tolmar Inc.
Collaborators
ICON plc
Responsible party
Sponsor
First posted
Apr 26, 2024
Start date
Jul 2, 2024
Primary completion
Nov 25, 2025
Completion
Nov 25, 2025
Last update
Oct 2, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Testosterone undecanoate

Start the discussion